Palantir stock wobbles premarket as UBS upgrade runs into AI jitters

February 27, 2026
Palantir stock wobbles premarket as UBS upgrade runs into AI jitters

New York, Feb 27, 2026, 08:18 EST — Premarket

  • Palantir slipped in premarket trading, following a 1.3% climb the previous day.
  • UBS bumped its rating up to “Buy” and stuck with a $180 price target. Rosenblatt, just starting coverage, set its target at $150.
  • U.S. January producer price numbers land at 8:30 a.m. ET, and traders are on alert.

Palantir Technologies (PLTR) slipped 0.4% to $135.38 before the bell Friday, pulling back after a 1.3% gain to $135.94 at Thursday’s close.

Wall Street’s giving Palantir another shot: UBS just bumped the stock to “Buy” from “Neutral,” sticking with its $180 price target. The firm called the shares “very attractive” now, after that steep 35% drop from the highs. Still, UBS pointed out investors remain uneasy about rivalry from hyperscalers and Databricks. Investing

Not the best backdrop. U.S. stock index futures edged lower, that “AI unease” still casting a shadow. The Nasdaq heads for its sharpest monthly slide since March 2025, with traders eyeing inflation numbers that could upend expectations for rates. Reuters

On Thursday, Rosenblatt kicked off its coverage with a “buy” call and set a $150 price target, according to Investing.com. That’s one more vote of confidence as the stock remains far under its October peak. Investing

Palantir’s push on its artificial intelligence platform has sharpened as more clients look for automation, with the data analytics firm catering to both government and the private sector. Following its most recent quarterly update, Palantir projected 2026 revenue in a range of $7.18 billion to $7.20 billion, and first-quarter sales expected between $1.53 billion and $1.54 billion. “Valuation question marks won’t disappear,” eToro analyst Zavier Wong said at the time. Reuters

The valuation back-and-forth hasn’t gone away. Palantir’s stock moves like an AI proxy: it leaps on bullish growth stories, but drops hard whenever investors pull back from pricey software names.

Here’s the simple setup: inflation comes in hotter than expected, yields tick up, and investors usually hit long-duration growth names first. If major clients pull back on spending, or if heavyweight cloud competitors start catching up, that “premium” rationale driving recent upgrades could face immediate scrutiny.

The focus now shifts to January’s U.S. Producer Price Index, set for release at 8:30 a.m. ET, just before the cash session kicks off.

Technology News Today

  • CRISPR variant ThermoCas9 targets tumor DNA via methylation fingerprint
    April 15, 2026, 1:47 PM EDT. Researchers from Wageningen University & Research and the Van Andel Institute report a CRISPR variant, ThermoCas9, that distinguishes tumor DNA from healthy DNA by DNA methylation-chemical tags that regulate gene activity. In Nature, the team shows ThermoCas9's PAM includes a human methylation site, allowing it to bind methylated DNA and cut tumor genomes while sparing unmethylated healthy DNA in cultured cells. The work marks the first CRISPR-based method to use methylation to target human cancer cells. While promising, results in cell culture are early and require validation in animals and, later, humans. If developed, this epigenetic fingerprint approach could yield highly selective cancer therapies that target malignant cells while leaving healthy tissue intact.